Jun 01, 2021

Starpharma (ASX:SPL)'s nasal spray achieves 98% efficacy against COVID-19

Starpharma (ASX:SPL)'s nasal spray achieves 98% efficacy against COVID-19

"Biopharmaceutical company Starpharma (ASX:SPL) claims the company’s nasal spray product is a highly efficacious means of protection from the UK variant of the coronavirus," Finance News Network reports. Read the full article here

 This contains certain forward-looking statements.